This Week in Biotech: Part 1
With 11 major biotech events this week, Part 1 of this two-part series looks at four FDA influenced actions of the week, including two fresh drug approvals, as well as a monster of a collaborative deal that could be worth billions for one lucky company!
Let the Hep C Drug War Begin
The approval of Gilead's Sovaldi sets the drug up to compete with Johnson & Johnson's Olysio, leaving Vertex Pharmaceuticals' and Merck's first-generation hepatitis C drugs in their wake. The fight may be short-lived, though, as patients wait for all-oral combinations from Gilead and AbbVie.
What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs
With Gilead (GILD), Johnson and Johnson (JNJ), AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK) rushing to get next generation hepatitis C drugs to market, here are the facts you need to see.
Soaring Hepatitis C Drug Prices Make Cures Costly
The arrival of Vertex's (VRTX) Incivek in 2010 kicked off a significant jump in the costs of treating hepatitis C. Those costs are likely to surge higher once Gilead's (GILD) and Johnson & Johnson's (JNJ) new drugs launch.
How Europe's Compassion for Hepatitis C Patients Helps Bristol-Myers
The European Medicines Agency has granted compassionate use for Bristol-Myers Squibb's daclatasvir, a promising hepatitis C drug currently seeking approval in Japan, for use with Gilead's sofosbuvir.